Characterization and Validation of a Canine Pruritic Model.

Autor: Aberg GA; Bridge Pharma Inc., 902 Contento Street, Sarasota, FL, USA., Arulnesan N; Nucro-Technics, Department of Toxicology, 2000 Ellesmere Road, Scarborough, ON, Canada., Bolger GT; Nucro-Technics, Department of Toxicology, 2000 Ellesmere Road, Scarborough, ON, Canada., Ciofalo VB; Bridge Pharma Inc., 902 Contento Street, Sarasota, FL, USA., Pucaj K; CroToxPath Consulting Inc., 1920 Ellesmere Rd, Scarborough, ON, Canada.
Jazyk: angličtina
Zdroj: Drug development research [Drug Dev Res] 2015 Aug; Vol. 76 (5), pp. 246-50. Date of Electronic Publication: 2015 Jul 29.
DOI: 10.1002/ddr.21261
Abstrakt: Preclinical Research The mechanisms mediating canine pruritus are poorly understood with few models due to limited methods for inducing pruritus in dogs. Chloroquine (CQ) is a widely used antimalarial drug that causes pruritus in humans and mice. We have developed a canine model of pruritus where CQ reliably induced pruritus in all dogs tested following intravenous administration. This model is presently being used to test antipruritic activity of drug candidate molecules. This publication has been validated in a blinded cross-over study in eight beagle dogs using the reference standards, oclacitinib and prednisolone, and has been used to test a new compound, norketotifen. All compounds reduced CQ-induced pruritus in the dog. The sensitivity of the model was demonstrated using norketotifen, which at three dose levels, dose-dependently, inhibited scratching events compared with placebo.
(© 2015 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: